Heterogeneity of ductal carcinoma in situ and its effects on management

Lancet Oncology

Volumn 7, Issue 9, 2006, Pages 756-765

  Mokbel, Kefah ^a   Cutuli, Bruno ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Radiation Oncology Department   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

AXILLARY LYMPH NODE; BREAST BIOPSY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DISEASE COURSE; ELDERLY CARE; ENDOMETRIUM CANCER; FOLLOW UP; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; INDIVIDUALIZATION; INTERMETHOD COMPARISON; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PATIENT CARE; PATIENT SELECTION; PLOIDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLINICAL TRIALS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE;

EID: 33747856742     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70861-0     Document Type: Review

References (82)

1. Lippman M. Why study ductal carcinoma in situ?. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott, Williams and Wilkins, Philapdelphia 12-16
2. Bobo J., Lee N., and Thames S. Findings from 752 081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 92 (2000) 971-976
3. Barreau B., de Mascarel I., Feuga C., et al. Mammography of ductal carcinoma in situ of the breast: review of 909 cases with radiographic-pathologic correlations. Eur J Radiol 54 (2005) 55-61
4. Ernster V., and Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr 22 (1997) 151-156
5. Pisano E., Gatsonis C., Hendrick E., et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353 (2005) 1773-1783
6. Boetes C., and Veltman J. Screening women at increased risk with MRI. Cancer Imaging 5 Spec No A (2005) S10-S15
7. Menell J., Morris E., Dershaw D., et al. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging. Breast J 11 (2005) 382-390
8. Mokbel K., Escobar P., and Matsunaga T. Mammary ductoscopy: current status and future prospects. Eur J Surg Oncol 31 (2005) 3-8
9. Zhao L., Freimanis R., Bergman S., et al. Biopsy needle technique and the accuracy of diagnosis of atypical ductal hyperplasia for mammographic abnormalities. Am J Surg 69 (2003) 757-762
10. Douglas-Jones A., Morgan J., Appleton M., et al. Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast. J Clin Pathol 53 (2000) 596-602
11. Badve S., A'Hern R., Ward A., et al. Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. Hum Pathol 29 (1998) 915-923
12. Bethwaite P., Smith N., Delahunt B., and Kenwright D. Reproducibility of new classification schemes for the pathology of ductal carcinoma in situ of the breast. J Clin Pathol 51 (1998) 450-454
13. Douglas-Jones A., Gupta S., Attanoos R., et al. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma. Histopathology 29 (1996) 397-409
14. Sanders M., Schuyler P., Dupont W., and Page D. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103 (2005) 2481-2484
15. Leonard G., and Swain S. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96 (2004) 906-920
16. Kerlikowske K., Molinaro A., Cha I., et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95 (2003) 1692-1702
17. Silverstein M., Poller D., Waisman J., et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345 (1995) 1154-1157
18. Lagios M., and Silverstein M. Ductal carcinoma in situ: the success of breast conservation therapy-a shared experience of two single institutional nonrandomized prospective studies. Surg Oncol Clin N Am 6 (1997) 385-392
19. Holland R., Peterse J., Millis R., et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11 (1994) 167-180
20. Idvall I., Anderson H., Ringberg A., and Ferno M. Are cellular polarisation and mitotic frequency prognostic factors for local recurrence in patients with ductal carcinoma in situ of the breast?. Eur J Cancer 39 (2003) 1704-1710
21. Silverstein M., Lagios M., Craig P., et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 77 (1996) 2267-2274
22. Baqai T., and Shousha S. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast. Histopathology 42 (2003) 440-447
23. Provenzano E., Hopper J., Giles G., et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 39 (2003) 622-630
24. Buerger H., Otterbach F., Simon R., et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast: evidence of multiple genetic pathways. J Pathol 187 (1999) 396-402
25. Aubele M., Mattis A., Zitzelsberger H., et al. Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer 85 (2000) 82-86
26. Wulfkuhle J., Sgroi D., Krutzsch H., et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 62 (2002) 6740-6749
27. Morrow M., Strom E., Basset L., et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 52 (2002) 256-276
28. Boyages J., Delaney G., and Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 85 (1999) 616-628
29. Baxter N., Virnig B., Durham S., and Tuttle T. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96 (2004) 443-448
30. Kricker A., and Armstrong B. Surgery and outcomes of ductal carcinoma in situ of the breast: a population-based study in Australia. Eur J Cancer 40 (2004) 2396-2402
31. Ernster V., Barclay J., Kerlikowske K., et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology and End Results program. Arch Intern Med 160 (2000) 953-958
32. Cutuli B., Lemanski C., Fourquet A., et al. French National Survey on DCIS: analysis of clinico-pathological features and treatments in 1289 patients. Eur J Cancer Suppl 3 (2005) 77
33. Cunnick G., and Mokbel K. Skin-sparing mastectomy. Am J Surg 188 (2004) 78-84
34. MacDonald H., Silverstein M., Mabry H., et al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg 190 (2005) 521-525
35. Ringberg A., Idvall I., Ferno M., et al. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast. Eur J Surg Oncol 26 (2000) 444-451
36. Cataliotti L., Distante V., Orzalesi L., et al. The Florence experience. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott Williams and Wilkins, Philadelphia 348-353
37. Tunon-de-Lara C., de-Mascarel I., Mac-Grogan G., et al. Analysis of 676 cases of ductal carcinoma in situ of the breast from 1971 to 1995: diagnosis and treatment-the experience of one institute. Am J Clin Oncol 24 (2001) 531-536
38. Cutuli B., Cohen-Solal-le Nir C., de Lafontan B., et al. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys 53 (2002) 868-879
39. Ottesen G., Graversen H., Blichert-Toft M., et al. Carcinoma in situ of the female breast: 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat 62 (2000) 197-210
40. Schwartz G. Treatment of subclinical ductal carcinoma in situ of the breast by local excision and surveillance: an update personal experience. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott Williams and Wilkins, Philadelphia 308-321
41. Arnesson L., and Olsen K. Linköping experience. In: Silverstein M. (Ed). Ductal carcinoma in situ of the breast (1997), Williams and Wilkins, Baltimore 373-377
42. Lagios M. The Lagios experience. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott Williams and Wilkins, Philadelphia 303-307
43. Wong J., Kaelin C., Troyan S., et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24 (2006) 1031-1036
44. Silverstein M. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186 (2003) 337-343
45. Silverstein M. An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncology (Williston Park) 17 (2003) 1511-1533
46. Fowble B. Overview of conservative surgery and radiation therapy: ductal carcinoma in situ. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott Williams and Wilkins, Philadelphia 287-302
47. Fisher B., Land S., Mamounas E., Dignam J., et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28 (2001) 400-418
48. Bijker N., Peterse J., Duchateau L., et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19 (2001) 2263-2271
49. Bijker N., Meijnen P., Peterse J., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer (EORTC) randomized phase III trial 10853. A study by EORTC Berast Cancer Coperatiove Group and EORTC Radiotherapy Group. J Clin Oncol 24 (2006) 3381-3387
50. Houghton J., George W., Cuzick J., et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362 (2003) 95-102
51. Emdin S., Granstrand B., Ringberg A., et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast-results of a randomised trial in a population offered mammography screening. Acta Oncol 45 (2006) 536-543
52. Fisher B., Land S., Mamounas E., Dignam J., Fisher E., and Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project Experience. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott Williams and Wilkins, Philadelphia 432-446
53. Bijker N., Peterse J., Fentiman I., et al. Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Br J Cancer 87 (2002) 615-620
54. Lagios M. Practical pathology of ductal carcinoma in situ: how to derive optimal data from the pathologic examination. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott, Williams and Wilkins, Philadelphia 207-221
55. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (1999) 1993-2000
56. Allred D., Bryant J., Lano S., et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP protocol B-24. Breast Cancer Res Treat 76 suppl 1 (2002) 536
57. Veronesi P., Intra M., Vento A., et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ?. Breast 14 (2005) 520-522
58. Silverstein M., Lagios M., Martino S., et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 16 (1998) 1367-1373
59. Cutuli B., Lemanski C., le Blanc M., et al. Local recurrences after DCIS therapy: diagnosis, treatment and outcome. Breast Cancer Res Treat 76 suppl 1 (2002) S36 (abstr 31)
60. Solin L., Fourquet A., Vicini F., et al. Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ. Eur J Cancer 41 (2005) 1715-1723
61. Warren J., Weaver D., Bocklage T., et al. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis. Cancer 104 (2005) 1840-1848
62. Vicini F., and Recht A. Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol 20 (2002) 2736-2744
63. Fourquet A., Zigal-Zafrani B., and Clough K. Breast-conserving surgery plus radiation therapy in ductal carcinoma in situ: the Institut Curie experience. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott Williams and Wilkins, Philadelphia 367-372
64. Solin L., Fourquet A., Vicini F., et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 50 (2001) 991-1002
65. Solin L., Fourquet A., Vicini F., et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103 (2005) 1137-1146
66. Silverstein M. Margin width as the sole predictor of local recurrence in patients with ductal carcinoma in situ of the breast. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott Williams and Wilkins, Philadelphia 482-493
67. Schwartz G., Solin L., Olivotto I., et al. Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999. Cancer 88 (2000) 946-954
68. Cutuli B., Fourquet A., Luporsi E., et al. Standards, options et recommandations 2004: prise en charge des carcinomes canalaires in situ du sein. www.fnclcc.fr/sor.htm (accessed September 2004)
69. Sigal-Zafrani B., Lewis J., Clough K., et al. Histological margin assessment for breast ductal carcinoma in situ: precision and implications. Mod Pathol 17 (2004) 81-88
70. Park C., Schmitt J., and Recht A. Joint center for radiation therapy experience. In: Silverstein M., Recht A., and Lagios M. (Eds). Ductal carcinoma in situ of the breast. 2nd edn. (2002), Lippincott Williams and Wilkins, Philadelphia 373-380
71. Vicini F., Kestin L., Goldstein N., et al. Relationship between excision volume, margin status, and tumor size with the development of local recurrence in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Surg Oncol 76 (2001) 245-254
72. Neuschatz A., DiPetrillo T., Steinhoff M., et al. The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer 94 (2002) 1917-1924
73. Mokbel K., Choy C., Leris C., et al. Predictors of positive margins after local excision of ductal carcinoma in situ. Am J Surg 181 (2001) 91-95
74. Bartelink H., Horiot J., Poortmans O., et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Eng J Med 435 (2001) 1378-1387
75. Cutuli B., Lemanski C., Cohen-Solal-Le-Nir C., et al. Ductal carcinoma in situ (DCIS) of the breast: what is the safest treatment?. Int J Radiat Oncol Biol Phys 57 suppl 1 (2003) S361
76. Cutuli B., Dilhuydy J., De Lafontan B., et al. Ductal carcinoma in situ of the male breast: analysis of 31 cases. Eur J Cancer 33 (1997) 35-38
77. Hittmair A., Lininger R., and Tavassoli F. Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma-a preliminary report. Cancer 83 (1998) 2139-2149
78. Cutuli B., Borel C., Dhermain F., et al. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol 59 (2001) 247-255
79. Wolden S., Hancock S., Carlson R., et al. Management of breast cancer after Hodkin's disease. J Clin Oncol 18 (2000) 765-772
80. Yahalom J., Pertrek J., Biddinger P., et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathlogic analysis of 45 events in 37 patients. J Clin Oncol 10 (1992) 1674-1681
81. Kell M., and Morrow M. An adequate margin of excision in ductal carcinoma in situ. BMJ 331 (2005) 789-790
82. Solin L. Is excision alone adequate treatment for low-risk ductal carcinoma-in-situ of the breast?. J Clin Oncol 24 (2006) 1017-1019